Lurasidone

Chemical formula: C₂₈H₃₆N₄O₂S  Molecular mass: 492.676 g/mol  PubChem compound: 213046

Active ingredient description

Lurasidone is a selective blocking agent of dopamine and monoamine effects indicated for the treatment of schizophrenia. Lurasidone binds strongly to dopaminergic D2- and to serotonergic 5-HT2A and 5-HT7 receptors. Lurasidone does not bind to histaminergic or muscarinic receptors.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code Group title Classification
N05AE05 N Nervous system → N05 Psycholeptics → N05A Antipsychotics → N05AE Indole derivatives
Discover more medicines within N05AE05

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title Information Source Document Type  
LATUDA Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC

Structural formula

Graphic representation of the active ingredient's molecular structure

External identifiers

CAS Substance: 367514-87-2
DrugBank Drug: DB08815
KEGG Drug: D04820
PubChem Compound: 213046
RxNorm Ingredient: 1040028
SNOMED-CT Concept: 703115008
Lurasidone (substance)
UNII Identifier: 22IC88528T
LURASIDONE

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.